| ACTIVESITE PHARMACEUTICALS, INC. Patent applications |
| Patent application number | Title | Published |
|---|
| 20110152533 | PRODRUGS OF INHIBITORS OF PLASMA KALLIKRIEN - The present invention provides prodrugs of compounds that inhibit the activity of plasma kallikrein (PK) and methods of preventing and treating plasma kallikrein dependent diseases or conditions, for example, diabetic macular edema, with the prodrugs having the formula: | 06-23-2011 |
| 20110065757 | METHODS FOR TREATMENT OF KALLIKREIN-RELATED DISORDERS - We have identified classes of kallikrein inhibitors as compounds that are useful in the reduction of vascular permeability (e.g., retinal vascular permeability and cerebral vascular permeability) and astrocyte activation. Diseases and conditions associated with increased vascular permeability include diabetic retinopathy, hemorrhagic stroke, and macular edema. Diseases and conditions associated with astrocyte activation include Alzheimer's disease, multiple sclerosis, Parkinson's disease, amyotrophic lateral sclerosis, Creutzfeldt-Jakob disease, stroke, epilepsy, and brain trauma. | 03-17-2011 |
| 20100130563 | INHIBITORS OF PLASMA KALLIKREIN - The present invention provides compounds that inhibit the activity of plasma kallikrein (PK) and methods of preventing and treating the formation of thrombin during or after a PK dependent disease or condition, for example, after fibrinolysis treatment. | 05-27-2010 |
